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How PrEPped Are Our Providers?
Assessing Vermont Primary Care Providers’ Knowledge and Awareness 
of Pre-Exposure Prophylaxis (PrEP) Options for HIV Prevention
Christopher Flynn
MS3 – Larner College of Medicine at the University of Vermont
Family Medicine Clerkship – Hinesburg Family Practice
AHEC Scholars Core Topic: Current and Emerging Health Issues
Pre-exposure Prophylaxis (PrEP): Medications, 
Use Metrics, and Associated Problems
Problem: Constant release of new data/guidelines can be 
difficult to keep track of “best” available PrEP medications 
and dosing strategies
◦ Approved PrEP medications: Truvada (tenofovir disoproxil fumarate-
emtricitabine; 2012 FDA approval) & Descovy (tenofovir 
alafenamide fumarate-emtricitabine; 2019 FDA approval)
◦ Dosing strategies: once daily pill vs. “on demand”, “event-driven”      
(2-1-1) 
◦ Further compounded by prior research indicating providers’ lack of 
training surrounding PrEP prescribing practices
Estimated PrEP users (as of 2018): 200,000-205,000 (US), 
187 (VT)
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HIV Statistics & Associated Costs
VT HIV Statistics (as of 2018)
Number of total diagnosed cases 711 
Newly diagnosed cases (2018) 18
MSM transmission for newly 
diagnosed cases (2018)
43%
Number of PrEP users 187 (94.7% male)
(Vermont) (Vermont)
Despite rising trend in number of PrEP users, number of cases 
per year remains relatively stable
Majority of VT’s cases are in Chittenden county
Estimated lifetime cost for early HIV diagnosis is >$400,000
◦ Prevention is the focus!
◦ $907,375 to VT for HIV federally funded grants/programs (FY2018)
Perspective of Members of the 
Community
One of the main issues we face is not asking the 
right screening questions of our patients—for 
example, a gay man versus a heterosexual man—
to truly understand their needs. This issue is 
further heightened by our patient population. 
With a seemingly decreased need for PrEP among 
our patients, this is not a situation we routinely 
face, thus I would imagine there would be greater 
unfamiliarity. Conversely, I would imagine a 
greater need for PrEP in regions of the state with a 
younger patient demographic.
-Family Medicine Provider
In the last year, as in-person appointments 
became restricted, HIV testing access was 
consolidated to a few core medical providers, 
which resulted in fewer tests and fewer PrEP 
referrals. I imagine, also, fewer people continued 
their prescriptions for PrEP, along with those more 
limited new prescriptions. We anticipate at 
Vermont CARES we should be able to resume in-
person rapid-result HIV testing this summer, and 
consequently we know guided referrals to PrEP 
will increase. One dilemma we face now is that 
the landscape for referrals and prior routines has 
changed dramatically for all providers, so we will 
be re-learning protocols for PrEP access in real-
time along with those we serve. 
-Peter Jacobsen, Executive Director of Vermont CARES
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Intervention & Methodology
Reviewed prior Family Medicine Clerkship projects focusing on PrEP as a 
novel preventative medicine to compare with multiple options currently 
available to patients
Providers (MDs/NPs) at the Hinesburg Family Medicine practice were 
asked to complete anonymous survey assessing awareness and 
prescribing practices of PrEP
Review of survey data highlighted varying levels of knowledge, as well 
as comfortability and confidence discussing PrEP with patients
Goal: Equip providers with updated guidelines to increase knowledge and 
confidence when discussing current options for PrEP with patients
Give information sheet to all providers in the practice regarding current clinical guidelines for PrEP
Survey Data Results
All respondents reported 
knowledge of PrEP and correctly 
identified its purpose
40% reported reading current 
PrEP clinical practice guidelines 
(CDC)
100% of respondents aware of 
Truvada use as PrEP vs. 20% 
aware of Descovy use as PrEP
Provider willingness/readiness to 
discuss and prescribe PrEP 
reported as very willing (60%) or 
somewhat willing (40%)
Providers’ familiarity with dosing 
regimens:
• Greater familiarity with once daily dosing 
(strongly agree + somewhat agree, 80%)
• Less familiar with “on-demand” dosing 
(somewhat agree + neither agree nor 
disagree, 100%)
Top provider-reported barriers 
for prescribing PrEP:
• Cost-related concerns (80%)
• Provider perception of patient risk status 
(60%)
• Lack of knowledge, training or experience 
with PrEP (40%)
• Time constraint (40%)
Survey Data Results (cont.)
Evaluation of Intervention
“Use it or lose it” phenomenon: relatively low number of PrEP prescriptions in the state potentially 
due to low need
◦ Less frequent discussion point between providers and patients, thus providers potentially less likely to keep 
current with updated guidelines
◦ Influence of provider’s perspective of perceived need for individual patient or community at large
Survey data along with community member interviews highlight implications of providers’ own biases 
impacting patient encounters
Despite small sample size, fair amount of variability emphasizes need for continued education efforts, 
especially for minority patient populations
Results of survey are largely qualitative
◦ Potential follow-up 1: Assess differences in PrEP prescribing/counseling practices among providers who 
reviewed PrEP info sheet vs. another family medicine practice with similar patient demographics
◦ Potential follow-up 2: Survey providers in the practice who reviewed PrEP info sheet and assess changes in 
comfortability and confidence in PrEP counseling/prescribing practices
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